Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma

NCT00891839 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00891839
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00891839 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Study of Bendamustine Hydrochloride in Combination With Rituximab in the Treatment of Patients With Relapsed/Refractory Mantle Cell Lymphoma
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2009
Completion date
May 31, 2014
Enrollment
45 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma